• 2020 06. GenePro SARS-CoV-2 Test Emergency Use Authorization from FDA 06. Listed on Kosdaq
• 2019 01. Winner of the 2019 Korean IP Awards
• 2018 04. Winner of the Prime minister citation of KOREA 07. New medical technology certificates from HIRA
  (GenesWell ddEGFR Mutation Test)
• 2017 02. Commendation from ministry of food and drug safety (GenesWell BCT) 05. Register of genetic testing agency about prognostic diagnostics for Breast Cancer 09. Manufacturing & Product approval (Class III) GenesWell ddEGFR Mutation Test from MFDS
• 2016 08. GENCURIX-GenoBio Strategic partnership 09. Winner of Korean New Medicine Award 2016 (GenesWell ddEGFR Mutation Test) 11. Manufacturing & Product approval (Class III) for GenesWell BCT from MFDS
• 2015 07. Obtained GMP certificate 11. GENCURIX-KT(Korea Telecom) JV Establishment (NGeneBio)
• 2014 03. ISO13485 Certification 04. NET(New Excellent Technology) certificate for breast cancer multigene test 08. Selected for Ministry of Health and Welfare in Korea led Korea-Singapore international R&D collaborative research support project
• 2013 11. Selected by Ministry of Science, ICT, and Future Planning’s technology development business companion diagnostics business unit for its #1 main project
• 2012 03. Signed joint research and development agreement (Seoul National University College of Pharmacy Molecular pathology and cancer genome research lab) 07. GENCURIX established R&D Center affiliate
• 2011 09. Established GENECURIX 09. Signed Breast cancer prognosis diagnostic technology transfer agreement (Seoul National University College of Pharmacy Molecular pathology and cancer genome research lab)